Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:APLS NASDAQ:DNTH NASDAQ:GHRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$82.24-2.8%$80.24$34.34▼$95.32$5.09B0.69944,762 shs119,905 shsAPLSApellis Pharmaceuticals$41.04+0.0%$31.12$16.10▼$41.14$5.25B-0.244.66 million shs2.32 million shsDNTHDianthus Therapeutics$86.38-0.8%$82.39$16.64▼$96.50$4.72B1.18915,520 shs74,262 shsGHRSGH Research$21.260.0%$16.64$9.46▼$24.66$1.32B1.27322,921 shs19,592 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+1.89%+4.77%-1.94%+29.16%+126.87%APLSApellis Pharmaceuticals-0.03%+0.15%+0.56%+81.67%+137.11%DNTHDianthus Therapeutics+0.32%-0.34%-2.95%+71.43%+344.72%GHRSGH Research-0.75%+2.66%+35.24%+38.68%+104.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$82.24-2.8%$80.24$34.34▼$95.32$5.09B0.69944,762 shs119,905 shsAPLSApellis Pharmaceuticals$41.04+0.0%$31.12$16.10▼$41.14$5.25B-0.244.66 million shs2.32 million shsDNTHDianthus Therapeutics$86.38-0.8%$82.39$16.64▼$96.50$4.72B1.18915,520 shs74,262 shsGHRSGH Research$21.260.0%$16.64$9.46▼$24.66$1.32B1.27322,921 shs19,592 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+1.89%+4.77%-1.94%+29.16%+126.87%APLSApellis Pharmaceuticals-0.03%+0.15%+0.56%+81.67%+137.11%DNTHDianthus Therapeutics+0.32%-0.34%-2.95%+71.43%+344.72%GHRSGH Research-0.75%+2.66%+35.24%+38.68%+104.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.78Moderate Buy$112.7337.09% UpsideAPLSApellis Pharmaceuticals 2.09Hold$35.72-12.95% DownsideDNTHDianthus Therapeutics 3.00Buy$117.8236.40% UpsideGHRSGH Research 2.73Moderate Buy$40.1388.77% UpsideCurrent Analyst Ratings BreakdownLatest GHRS, APLS, APGE, and DNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026APLSApellis Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C-)5/6/2026DNTHDianthus Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$103.00 ➝ $105.005/1/2026APGEApogee Therapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.005/1/2026APGEApogee Therapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.004/21/2026GHRSGH Research Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026APGEApogee Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DNTHDianthus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026APLSApellis Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$26.00 ➝ $41.004/9/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$98.004/8/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/2/2026APLSApellis Pharmaceuticals Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/AAPLSApellis Pharmaceuticals$1.00B5.23$0.21 per share196.33$2.93 per share14.01DNTHDianthus Therapeutics$2.04M2,314.90N/AN/A$11.41 per share7.57GHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.22N/AN/AN/AN/A-36.77%-34.87%N/AAPLSApellis Pharmaceuticals$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%7/30/2026 (Estimated)DNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%N/AGHRSGH Research-$48.26M-$0.80N/AN/AN/AN/A-16.30%-15.77%5/14/2026 (Estimated)Latest GHRS, APLS, APGE, and DNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026GHRSGH Research-$0.27N/AN/AN/AN/AN/A5/11/2026Q1 2026APGEApogee Therapeutics-$1.12-$1.06+$0.06-$1.06N/AN/A5/7/2026Q1 2026APLSApellis Pharmaceuticals-$0.2888$0.15+$0.4388$0.15$208.91 million$268.30 million5/5/2026Q1 2026DNTHDianthus Therapeutics-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 million3/9/2026Q4 2025DNTHDianthus Therapeutics-$0.97-$1.43-$0.46-$1.43$0.40 million$0.57 million3/6/2026Q4 2025GHRSGH Research-$0.29-$0.23+$0.06-$0.23N/AN/A3/2/2026Q4 2025APGEApogee Therapeutics-$1.05-$1.03+$0.02-$1.03N/AN/A2/24/2026Q4 2025APLSApellis Pharmaceuticals-$0.39$0.47+$0.86-$0.45$199.28 million$199.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A26.5726.57APLSApellis Pharmaceuticals0.873.633.16DNTHDianthus TherapeuticsN/A29.2529.25GHRSGH ResearchN/A34.1334.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%APLSApellis Pharmaceuticals96.29%DNTHDianthus Therapeutics47.53%GHRSGH Research56.90%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%APLSApellis Pharmaceuticals6.80%DNTHDianthus Therapeutics3.02%GHRSGH Research41.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.85 million46.82 millionOptionableAPLSApellis Pharmaceuticals770128.02 million119.32 millionOptionableDNTHDianthus Therapeutics8054.67 million53.02 millionOptionableGHRSGH Research1062.03 millionN/AOptionableGHRS, APLS, APGE, and DNTH HeadlinesRecent News About These CompaniesGH Research (GHRS) Expected to Announce Quarterly Earnings on ThursdayMay 6, 2026 | americanbankingnews.comGH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 6, 2026 | marketbeat.comGH Research Raises $111 Million in Completed Share Offering to Fund Depression PipelineApril 30, 2026 | tipranks.comGH Research (GHRS) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comGH Research Announces Pricing of $117.5 Million Underwritten OfferingApril 29, 2026 | globenewswire.comGH Research (NASDAQ:GHRS) Reaches New 12-Month High - Here's WhyApril 20, 2026 | marketbeat.comGH Research: WH Decision On Psychedelics To Treat Depression Makes Bull CaseApril 20, 2026 | seekingalpha.comGH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental IllnessApril 20, 2026 | globenewswire.comGH Research PLC (NASDAQ:GHRS) Sees Large Decline in Short InterestApril 17, 2026 | marketbeat.comHere's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn SituationApril 4, 2026 | finance.yahoo.comGH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent EfficacyMarch 25, 2026 | tipranks.comGH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRDMarch 25, 2026 | globenewswire.comWhat Does GH Research PLC (GHRS)’s Clinical Progress Updates Say?March 25, 2026 | insidermonkey.com5 Best Psychedelic Stocks to Buy in 2026March 24, 2026 | insidermonkey.comGH Research to Join Stifel 2026 Virtual CNS Forum Fireside ChatMarch 16, 2026 | tipranks.comCanaccord Genuity Reaffirms Their Buy Rating on GH Research (GHRS)March 12, 2026 | theglobeandmail.comGH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3March 10, 2026 | seekingalpha.comGH Research (NASDAQ:GHRS) Developments Capture Attention Across Nasdaq FuturesMarch 6, 2026 | kalkinemedia.comKGH Research Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 5, 2026 | globenewswire.comRBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics SymposiumFebruary 20, 2026 | finance.yahoo.comRBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics SymposiumFebruary 18, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGHRS, APLS, APGE, and DNTH Company DescriptionsApogee Therapeutics NASDAQ:APGE$82.24 -2.37 (-2.80%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Apellis Pharmaceuticals NASDAQ:APLS$41.04 +0.02 (+0.04%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Dianthus Therapeutics NASDAQ:DNTH$86.38 -0.74 (-0.85%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.GH Research NASDAQ:GHRS$21.26 0.00 (-0.02%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
